CTY
City Therapeutics Inc.
There isn't enough reported data to score CTY yet.
CTY Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Healthy | |
| Healthy | |
| Healthy |
CTY's profitability, cash flow and balance sheet are currently healthy, but its revenue is weak.
CTY PE Valuation
CTY has no meaningful PE right now: it lost money over the past year.
CTY Forward outlook
There aren't enough analyst estimates for CTY to show an outlook.
CTY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2020 | $0.00 | $0.00 |
| Q1 2020 | $0.00 | $0.00 |
| Q4 2019 | $0.00 | $0.00 |
| Q3 2019 | $0.00 | $0.00 |
| Q2 2019 | $0.00 | $0.00 |
| Q1 2019 | $0.00 | $0.00 |
| Q4 2018 | $0.00 | $0.00 |
| Q3 2018 | $0.00 | $0.00 |
CTY lost $0.00 per share over the past year, a bigger loss than the year before.
CTY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2020 | $524M | -74% |
| Q1 2020 | $1.9B | -6.7% |
| Q4 2019 | $2B | -4.8% |
| Q3 2019 | $2B | -5.1% |
| Q2 2019 | $2.1B | -2.4% |
| Q1 2019 | $2.1B | -3.5% |
| Q4 2018 | $2.1B | 0% |
| Q3 2018 | $2.1B | +0.4% |
CTY's revenue has slid since its 2015 peak: $524M last quarter, down 74% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2020 | 130% | +93 points |
| Q1 2020 | 41% | +3.6 points |
| Q4 2019 | 31% | -1.3 points |
| Q3 2019 | 37% | +3.3 points |
| Q2 2019 | 37% | +6.8 points |
| Q1 2019 | 37% | +7.3 points |
| Q4 2018 | 32% | +4 points |
| Q3 2018 | 33% | +7.2 points |
CTY's operating margin was 130% last quarter, up 93 points from the same quarter a year ago, near the top of its range since 2013.
CTY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2020 | $410M | -25% |
| Q1 2020 | $468M | +5.4% |
| Q4 2019 | $737M | -11% |
| Q3 2019 | $552M | -19% |
| Q2 2019 | $544M | -34% |
| Q1 2019 | $444M | +6.5% |
| Q4 2018 | $831M | +120% |
| Q3 2018 | $679M | +231% |
CTY's free cash flow has been positive every quarter for seven years: $2.2B over the past year, down 13% from the year before.
CTY Total Shares
| Quarter | Spent |
|---|---|
| Q2 2020 | $3M |
| Q1 2020 | $8M |
| Q4 2019 | $1M |
| Q3 2019 | $4M |
| Q2 2019 | $2M |
| Q1 2019 | $9M |
| Q4 2018 | $1M |
| Q3 2018 | $5M |
CTY spent $16M buying back its own shares over the past year, down 5.9% from the year before.
CTY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2020 | 1.3x | Healthy |
| Q1 2020 | 1.3x | Healthy |
| Q4 2019 | 1.6x | Healthy |
| Q3 2019 | 1.4x | Healthy |
| Q2 2019 | 1.4x | Healthy |
| Q1 2019 | 1.4x | Healthy |
| Q4 2018 | 1.5x | Healthy |
| Q3 2018 | 1.5x | Healthy |
CTY's net debt is about 1.3 years of its operating earnings (EBITDA), about the same as a year ago.
CTY Weekly Momentum
As of the close on Nov 12, 2026: $18.98.
CTY PE vs Healthcare Sector
CTY has no meaningful PE right now: it lost money over the past year.
CTY Weekly Moving Averages
As of the close on Nov 12, 2026: $18.98.
CTY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2026 YTD | $22.4 | $19.0 | -15% |
It's down 15% so far in 2026.